
A
B16-F10
n=5/group
1. Untreated (IgG control)
2. CD39i (POM-1, every day 5mg/kg)
3. αCD4 + CD39i (every 3 days 400µg/dose)
4. αCD8 + CD39i (every 3 days 400µg/dose)
Tumor implant
CD4 or CD8 depletion
Days
0
+4
+7
+21
+35
1. Tumor growth
2. Survival
CD39i treatment initiation
Treatment discontinue
B
non depleted
CD4 depleted
CD8 depleted
CD4
CD8
CD3
C
Day +4
Day +7
Day +11
Day +14
Day +18
Day +21
Tumor volume (mm³)
CD39i
αCD4
αCD8
vs n.s
vs P=8x10⁻⁴
vs P=0.04
vs n.s
vs P=0.004
vs P=5x10⁻⁴
vs P=0.002
vs n.s
vs P=2x10⁻⁴
vs P=0.01
vs P=0.01
vs n.s
vs P=1x10⁻⁴
vs P=0.01
vs P=0.007
vs n.s
vs P=0.003
D
Survival (%)
Days
Untreated
CD39i
αCD4 + CD39i
αCD8 + CD39i
vs P=0.01
vs P=0.03
vs n.s
vs n.s
vs P=0.003
E
Untreated
CD39i
αCD4+CD39i
αCD8+CD39i
Tumor volume (mm³)
Days
F
SSC
GFP
B16-F10-GFP+
n=5/group
1. Untreated
3. CD39i (POM-1, every day 5mg/kg)
Tumor implant
Treatment initiation
Treatment discontinue
Days
0
+4
+14
1. Cytokine measurement
2. T cell proliferation
3. Cell profiling
4. ATP measurement
G
Gated on CD45⁺CD3⁺CD8⁺ cells
Granzyme B (%)
Perforin 1 (%)
ns
CD39i
H
Untreated
CD39i
IFNγ⁺
TNFα⁺
IL-2⁺
40.2
78.3
64.7
69.5
10.8
18
FSC
Gated on CD45⁺CD3⁺CD8⁺ cells
IFNγ⁺ (%)
TNFα⁺ (%)
IL-2⁺ (%)
0.04
ns
CD39i
I
Untreated
CD39i
Count
43.1
40.4
48.4
76.9
74.4
72.4
CFSE
Gated on Thy1.2⁺CD8⁺ cells
Proliferation (%)
3x10⁻⁴
CD39i
J
Gated on CD45⁺CD3⁺CD8⁺ cells
Gated on GFP⁺ cells
CD39 (%)
ns
CD39i
K
Whole tumor tissue
GFP⁺ cells
ATP (nM)
0.02
CD39i